幹細胞技術および用途の世界市場：がん治療、心臓血管系疾患治療、中枢神経系疾患治療...市場調査レポートについてご紹介

1. Report Overview
1.1 Global Stem Cell Technologies and Applications Market Overview
1.2 Global Stem Cell Technologies and Applications Market Segmentation
1.3 Why you Should Read This Report
1.4 How this Report Delivers
1.5 Key Questions Answered by This Report
1.6 Who is Report for?
1.7 Research and Analysis Methods
1.8 Frequently Asked Questions (FAQ)
1.9 Some Associated Reports
1.10 About Visiongain

2. Introduction to Stem Cell Technologies and Applications
2.1 What are Stem Cells? Defining Characteristics
2.2 Timeline of Stem Cell Research
2.3 Embryonic Stem Cells (ESCs) Enter the Picture
2.4 Classifying Stem Cells by Potency
2.4.1 Post Fertilisation and Germ Layers
2.5 The Main Types of Stem Cells and Their Properties
2.6 iPSCs: The Benefits of ESCs, but Without the Downsides?
2.6.1 CIRM hPSC Repository Launches 300 iPSC Lines
2.7 Parthenogenetic Stem Cells: Scientific Background
2.7.1 Are they Ethical Alternatives to ESCs? What are the Commercial Applications?
2.8 Autologous Versus Allogeneic Stem Cells
2.8.1 Are Universal Stem Cell Products Possible?
2.9 Phases of Clinical Trials
2.10 Scope of this Report

3. International Developments and Stem Cell Regulatory Environments
3.1 Regulatory Environment in the US
3.1.1 Dynamic Biotechnology Sector and Liberal Stance on Patents
3.1.2 Understanding ‘Homologous’ Use
3.1.3 Controversy Surrounding ESC Research
3.1.4 NIH ESC Stem Cell Registry: Has Made Good Progress, but not Enough for its Critics
3.1.5 CIRM Allocates Close to $2bn in Stem Cell Funding into Various Channels
3.1.6 FDA vs Regenerative Sciences
3.1.7 Are Stem Cells Clinics the ‘Wild West’ of Medicine?
3.1.8 Stem Cell Clinics Using Loopholes to Avoid Oversight?
3.1.9 FDA Releases Three New Draft Guidances, but is it Doing Enough?
3.2 Regulatory Environment in Europe
3.2.1 Unified Overarching System of Regulation Across EU
3.2.2 Difference Between EU Member States Regarding hESC Research
3.2.3 European Court of Justice Performs an U-Turn and Clears Path Towards Stem Cell Patents
3.2.4 The UK: A Leader in European Stem Cell Research
3.3 Regulatory Environment in Japan
3.3.1 Liberal Stance on hESC but with Excessive Bureaucracy?
3.3.2 Japan: A Pioneer in iPSC Research, Although First In-Human Trial has been Suspended
3.3.3 The STAP Cell Events: Excitement Dashed
3.3.3.1 Riken Concludes Investigation
3.3.4 Government Committed to Regenerative Medicines and iPSC Research
3.3.5 Japan Becomes Very Attractive Market for Stem Cell Companies due to Favourable Regulatory Changes
3.4 Regulatory Environment in South Korea
3.4.1 Highs and Lows with Regard to hESC Research
3.4.2 Regulators are Quick to Approve Therapies, Although this has Drawn Criticism
3.4.3 Tracheal Transplant Patient Dies
3.5 Chinese Regulatory Environment
3.5.1 Liberal Regulation on Stem Cells and Very High Number of Stem Cell Clinical Trials Taking Place in the Country
3.5.2 Stem Cell Medical Tourism Very Popular
3.5.3 CFDA Releases New Stem Cell Draft Guidance
3.6 Israeli Regulatory Environment: A Strong Presence in Stem Cell Research
3.7 Indian Regulatory Environment: Emerging Stem Cell Industry – in Need of more Regulation?

4. Stem Cell Technologies and Applications: World Market 2015-2026
4.1 Therapeutic Applications Versus Non-Therapeutic Applications of Stem Cells
4.2 Regional Breakdown of the World Market
4.3 Market Segmentation
4.4 Stem Cell Technologies and Applications Market: Forecast 2015-2026
4.5 Stem Cell Technologies and Applications Market: Forecast by Segment 2015-2026
4.6 How Will Segmental Market Shares Change to 2026?
4.6.1 Which Segments will Grow the Most?
4.7 Stem Cell Technologies and Applications Market: Drivers and Restraints 2015-2026

5. Stem Cell Cancer Therapeutics Segment 2015-2026
5.1 Stem Cell Cancer Therapeutics: Overview and Current Status
5.2 Stem Cell Cancer Therapeutics: Market Forecast 2015-2026
5.3 Haematopoietic Stem Cell Transplantation (HCST)
5.3.1 An Established Treatment for Haematological Cancers
5.3.2 Autologous HSCT: Dominant Form of HSCT
5.3.3 Autologous Versus Allogeneic HSCT: Advantages and Disadvantages
5.3.4 GvHD: The Major Issue for HSCT
5.3.5 Strengths and Weaknesses of the Three Major Sources of HSCs
5.3.6 What is Cord Blood?
5.3.6.1 Cord Blood Use Rising in HSCT
5.3.7 Number of HSCT Operations Performed Worldwide, Split by Autologous Versus Allogeneic HSCT, 2012-2014
5.3.7.1 Numbers of HSCT Operations Performed in Europe, Split by Donor Type, 2003-2012
5.3.8 HSCT Costs and Medicare Coverage
5.3.9 The Indications which can be treated with HSCT: Haematological Malignancies are the Major Indications
5.3.10 HSCT has the Potential to Address Multiple Cancers, which Represent a $20bn+ Market
5.4 From Procedures to Products: Cord Blood Stem Cell Approvals
5.4.1 Hemacord (New York Blood Center): The First FDA-Approved Cord Blood Product
5.4.1.1 Hemacord Awarded Prix Galien ‘Best Biotechnology Product’ Award
5.4.2 HPC, Cord Blood (ClinImmune Labs / University of Colorado Blood Bank)
5.4.3 Ducord (Duke University School of Medicine)
5.4.4 Allocord (SSM Cardinal Glennon Children’s Medical Center)
5.4.5 HPC, Cord Blood BLA 125432 (LifeSouth Community Blood Centers)
5.5 Stem Cell Cancer Therapeutics Pipeline
5.5.1 Agenmestencel-T (Apceth)
5.5.2 CLT-008 and CLT-009 (Cellerant Therapeutics): Company Receives $47.5m Grant from US Government
5.5.3 ProHema (Fate Therapeutics)
5.5.3.1 ProTmune: Company Planning to file IND in Second Half of 2015
5.5.4 StemEx and NiCord (Gamida Cell)
5.5.4.1 StemEx Shows Improved Survival at 100 Days – but FDA Wants Another Clinical Trial
5.5.4.2 Copper Chelator Based Technology
5.5.4.3 NiCord
5.5.4.4 NiCord: Company Aiming for a “Paradigm Shift” in Treatment Practice, Receives Orphan Drug Designation
5.5.4.5 NiCord: Gamida Cell Reaches Agreement on Phase 3 Design Outline with the FDA and EMA
5.5.4.6 NAM Technology Platform
5.5.4.7 Novartis Chooses Not to Buy Gamida Cell
5.5.5 MSC-100-IV (Previously Known as Prochymal) and Unnamed MPC-Expanded Cord Blood Product (Mesoblast)
5.5.5.1 MSC-100-IV: World’s First Approved Stem Cell Drug Outside of South Korea
5.5.5.2 MSC-100-IV: Culture Expanded and Able to Treat GvHD
5.5.5.3 An Important Role to Play in the Future of HSCT
5.5.5.4 Wins Approval in Japan, through Partner JCR Pharmaceuticals, and Phase 3 Trial will Support US BLA
5.5.5.5 MSC-100-IV / Temcell HS Injection Revenue Forecast 2015-2026
5.5.5.6 MPC-Expanded Cord Blood Product in a Phase 3 Trial for Haematological Malignancies
5.5.6 HSC835 (Novartis)
5.5.6.1 Novartis Enters Partnership Agreement with Regenerex to Develop Novel Cell-Based Therapies
5.5.6.2 Collaborations with Intellia Therapeutics and Caribou for CRISPR and HSCs
5.5.7 Ancillary Products for the HSCT Setting
5.5.8 Targeting of Cancer Stem Cells (CSCs)
5.6 Stem Cell Cancer Therapeutics: Drivers and Restraints 2015-2026

6. Stem Cell Cardiovascular Therapeutics Segment 2015-2026
6.1 Stem Cell Cardiovascular Therapeutics: Overview and Current Status
6.2 Stem Cell Cardiovascular Therapeutics: Market Forecast 2015-2026
6.3 Cardiovascular Diseases Make up a Large part of the Global Pharmaceutical Market
6.3.1 Stem Cell Treatments for Stroke: Touched Upon in This Chapter but mainly Covered under Central Nervous System Therapeutics
6.3.2 Cardiovascular and Cerebrovascular Conditions are the World’s Most Fatal Diseases
6.3.3 AMI, CLI and Stroke: Major Ischaemic Disease Targets
6.4 The State of Stem Cell Research for Cardiovascular Diseases
6.4.1 Practical Advantages to Choosing the Heart as a Target for Stem Cell R&D
6.4.2 Defining Cardiovascular Stem Cells: Scientific Context
6.5 The Mysterious Effects of Stem Cells in the Heart
6.5.1 MSCs in the Heart: Evidence to Support their Use, as well as Doubts over their Efficacy
6.5.2 Cardiosphere-Derived Cells, hESC-Derived Cardiomyocytes and C-kit Cells
6.6 Stem Cell Cardiovascular Therapeutics on the Market
6.6.1 Hearticellgram-AMI (Pharmicell)
6.6.1.1 One of the First Approved Cardiovascular Stem Cell Treatments in the World
6.6.1.2 Hearticellgram-AMI Sales Estimates 2012-2014
6.6.1.3 Will Have Difficulty Getting Approved in Markets Outside of South Korea
6.6.1.4 Hearticellgram-AMI Revenue Forecast 2015-2026
6.6.2 CardioRel (Reliance Life Sciences)
6.6.2.1 Available on the Indian Market, but Does Data Back it up?
6.6.2.2 CardioRel Revenue Forecast 2015-2026
6.7 Stem Cell Cardiovascular Therapeutics Pipeline
6.7.1 Ixmyelocel-T (Vericel Corporation)
6.7.1.1 Vericel Shifts Focus Away from CLI and Towards DCM
6.7.1.2 Currently in Phase 2b, with a Possible Launch in 2019
6.7.2 Alecmestencel-T (Apceth)
6.7.3 Arteriocyte: Using its ‘Magellan System’ to Treat CLI
6.7.4 MultiStem (Athersys) for Myocardial Infarction and Stroke
6.7.4.1 Updates from Athersys Regarding Trial Status: Did MultiStem Fail in Stroke, or was it just Being Assessed in the Wrong Treatment Window?
6.7.5 Baxter: Phase 3 CD34+ Stem Cell Therapy for Refractory Angina
6.7.6 CardiAMP (BioCardia) for Heart Failure: Scheduled to Finally Begin Phase 3 in January 2016
6.7.7 MyoCell (U.S. Stem Cell, Inc. – Formerly Bioheart): Autologous ‘Muscle Stem Cell’ Therapy
6.7.7.1 MyoCell: Is the Company Still Trying to Secure Funds to Restart the Phase 2/3 MARVEL Trial?
6.7.7.2 MyoCell: MIRROR Trial on Hold
6.7.7.3 MyoCell SDF-1: Improved Version of MyoCell
6.7.7.4 MyoCell SDF-1 Phase 1 Trial (Regen): Another Trial Put on Hold
6.7.8 CAP-1001 and CAP-1002 (Carpricor): Cardiospehere-Derived Cells for Heart Repair
6.7.9 Ceylad (Formerly Cardio3): Proprietary Cardiopoiesis Technology Platform – Can be Applied to Various Stem Cell Sources
6.7.9.1 C-Cure: Stem Cell Therapy for the Treatment of Heart Failure
6.7.9.2 C-Cure: Two Phase 3 Trials Under Way
6.7.10 Mesoblast: Mesenchymal Precursor Cells for Heart Failure and Myocardial Infarction
6.7.10.1 CEP-41750: Phase 3 for Congestive Heart Failure (CHF), Chief Executive Provides Update
6.7.10.2 CEP-41750: Promising Phase 2 Results, More Effective in a Particular Subset of Heart Failure Patients?
6.7.10.3 Phase 2 Trial of MPCs in Acute Myocardial Infarction
6.7.11 Caladrius Biosciences: Will not Continue Development of CLBS10, the Company’s Former Lead Candidate
6.7.11.1 CLBS12 for CLI: Due to Start Phase 2 in Japan in January 2016
6.7.12 Stemedica Cell Technologies: ‘Ischaemic-Tolerant’ Stem Cell Platform
6.7.12.1 Trials in Myocardial Infarction and Stroke
6.7.13 Gemacell and Cryocell (Human Stem Cells Institute): Awaiting Important Russian Legislation to be Passed Before Development can Continue
6.8 Stem Cell Cardiovascular Therapeutics: Drivers and Restraints 2015-2026

7. Stem Cell Central Nervous System Therapeutics Segment 2015-2026
7.1 Stem Cell Central Nervous System Therapeutics: Overview and Current Status
7.2 Stem Cell Central Nervous System Therapeutics: Market Forecast 2015-2026
7.3 The State of Stem Cell Research in CNS Diseases
7.3.1 Stem Cells are the Best Hope for Many Serious CNS Conditions
7.3.2 Awaiting a First Breakthrough Approval
7.3.3 Human Neural Stem Cells (NSCs) Successfully Isolated
7.3.4 NSCs Reach the Clinic Without Serious Controversy
7.3.5 CNS Disorders are a Major Focus for ESC Research
7.3.6 MSCs: Can Glial Cell and Astrocyte Formation Help Neurological Conditions?
7.4 Progress in Specific CNS Conditions
7.4.1 HSCT in MS: Could ‘Resetting’ the Immune System Treat MS?
7.4.1.1 Clinical Trials Involving HSCT in MS
7.4.1.2 Barriers to Overcome Before HSCT Could Become an Established Therapy for MS
7.4.2 ALS: Could this Rare Disease be the First Neurodegenerative Condition for Stem Cell Treatment?
7.4.3 Parkinson’s Disease: Field Recovering after Voluntary Moratorium on Stem Cell Research by Many Western Nations Ends
7.4.4 Dry Age-Related Macular Degeneration: A Major Unmet Need
7.5 Several Multi-Billion Dollar Markets are Open to Stem Cell Developers if they can Translate the Potential of Stem Cells into Therapies
7.6 Stem Cell Central Nervous System Therapeutics Pipeline
7.6.1 MA09-hRPE (Ocata Therapeutics): Stem Cells for Eye Diseases
7.6.1.1 Orphan Drug Status in both the US and EU
7.6.1.2 Current Clinical Trials in SMD
7.6.1.3 Early Signs of Efficacy
7.6.1.4 Has Moved into Phase 2 in AMD
7.6.2 NurOwn (BrainStorm Cell Therapeutics): Neurotrophic Factor – Releasing Stem Cells for ALS
7.6.2.1 Phase 2 Trial in 48 ALS Patients Underway
7.6.2.2 Phase 2a Results Demonstrate “Statistically Significant Effect”
7.6.3 International Stem Cell Corporation: Company Signals Intent to Start Phase 1/2a Study in PD Soon
7.6.4 Neuralstem: Allogeneic NSCs for Synaptic Repair and Neuroprotection
7.6.4.1 NSI-566 in ALS
7.6.4.2 NSI-566 in ALS: Encouraging Data from Completed Phase 2 Trial
7.6.4.3 NSI-566 for Chronic Spinal Cord Injury: Phase 1 Top-Line Data Expected Q4 2015
7.6.4.4 NSI-566 for Ischaemic Stroke: Phase 1/2 Trials Underway in China
7.6.4.5 Preclinical Investigation in 11 Other Indications
7.6.5 PF-05206388 (Pfizer and the London Project to Cure Blindness): Finally Begins Phase 1Trial, with first Successful Surgery
7.6.6 Q-Cells (Q Therapeutics): Phase 1/2 Trial Begins
7.6.7 ReNeuron: CTX Neural Cell Line and its Advantages
7.6.7.1 CTX for Stroke
7.6.7.2 CTX for Stroke: Long-Term PISCES Study Shows Promising Results
7.6.7.3 CTX for Stroke: Undergoing Phase 2, Using Highest Cell Dose from PISCES Study
7.6.8 SB623 (SanBio): Enters Phase 2 for Stroke, as well as for Traumatic Brain Injury
7.6.9 StemCells, Inc: A Leader in Neural Stem Cells
7.6.9.1 HuCNS-SC for Pelizaeus-Merzbacher Disease: Undergoing Second Phase 1 Trial
7.6.9.2 HuCNS-SC for NCL: Second Phase 1 Trial Withdrawn
7.6.9.3 HuCNS-SC for Spinal Cord Injury: Phase 2
7.6.9.4 HuCNS-SC for AMD: Top-Line Phase 1/2 Results Released
7.7 Stem Cell Central Nervous System Therapeutics: Drivers and Restraints 2015-2026

8. Stem Cell Therapeutics in Other Disease Areas 2015-2026
8.1 Stem Cell Therapeutics in Other Disease Areas: Overview and Current Status
8.2 Stem Cell Therapeutics in Other Disease Areas: Market Forecast 2015-2026
8.3 Stem Cell Therapeutics in Other Disease Areas: Therapies on the Market
8.3.1 Osteocel Plus (NuVasive)
8.3.1.1 Osteocel to Osteocel Plus: Passing Through Different Companies and Patent Disputes
8.3.1.2 The Leading Stem Cell Orthobiologic
8.3.1.3 Is it Better than Autograft?
8.3.1.4 Osteocel Plus Revenue Forecast 2015-2026
8.3.2 Trinity Evolution and Trinity Elite (Orthofix): Stem Cell Orthobiologics
8.3.2.1 Positive Results from New Trial in Foot and Ankle Procedures
8.3.2.2 Trinity Evolution and Elite Revenue 2010-2014
8.3.2.3 Trinity Evolution and Elite Revenue Forecast 2015-2026
8.3.3 CARTISTEM (MEDIPOST)
8.3.3.1 CARTISTEM: The World’s First Allogeneic Stem Cell Drug
8.3.3.2 CARTISTEM: Latest Updates Includes Results from Phase 3 Trial, Initiation of Phase 1/2 Trial in the US
8.3.3.3 CARTISTEM: Revenues 2013 – H1 2015
8.3.3.4 CARTISTEM Revenue Forecast 2015-2026
8.3.4 Allostem (Allosource)
8.3.5 Map3 (RTI Surgical)
8.3.6 ReliNethra for Ocular Surface Damage (Reliance Life Sciences)
8.3.7 Cupistem (Anterogen)
8.4 Stem Cell Therapeutics for Other Diseases: Research Areas
8.4.1 HSCT for Orphan Diseases
8.4.2 Potential for Genetically Modified Stem Cells for HIV and Other Diseases?
8.4.3 Stem Cells Contribute to the Osteogenesis Process in Bone Repair
8.4.4 Stem Cells Gaining Increasing Importance in Bone Graft Market, but whether these are True ‘Stem Cell Products’ is Debatable
8.4.5 Stem Cells also have Potential in Autoimmune Disorders
8.4.6 Potential Cure for Diabetes?
8.4.6.1 Clinical Stage Programmes in Diabetes
8.4.7 Stem Cells in Active Liver Repair
8.4.8 Long-Term Possibilities
8.5 Stem Cell Therapeutics in Other Disease Areas: Pipeline
8.5.1 ALLO-ASC and ALLO-ASC-DFU (Anterogen)
8.5.2 MultiStem (Athersys): Fails Phase 2 Ulcerative Colitis, Still Undergoing Phase 1 as Immunomodulation Therapy after Liver Transplantation
8.5.3 BioTime: Multiple Subsidiaries Focused on Regenerative Medicine
8.5.3.1 AST-OPC1 and AST-VAC2 (Asterias Biotherapeutics)
8.5.3.2 OpRegen (Cell Cure Neurosciences)
8.5.3.3 Other BioTime Subsidiaries Related to Stem Cells: OncoCyte, ReCyte, ESI Bio, LifeMap Sciences Etc.
8.5.4 Calimmune: Dual Anti-HIV Gene Therapy via Stem Cells
8.5.5 (PDA-001 and PDA-002) Celgene Corporation
8.5.6 ReJoin (Cellular Biomedicine Group): Interim Results from the MSCs for Knee Osteoarthritis
8.5.7 PNEUMOSTEM (MEDIPOST)
8.5.7.1 NEUROSTEM (MEDIPOST): Undergoing Phase 1/2 Trial and Obtains Patents Around the Globe
8.5.8 Translational Biosciences: Set Up for the Sole Purpose of Conduction Stem Cell Clinical Trials, Five Phase 1/2 Trials Ongoing
8.5.9 Mesoblast: MPCs for Various Indications
8.5.9.1 MPC-300-IV in Diabetes
8.5.9.2 MPC-300-IV in Rheumatoid Arthritis
8.5.9.3 MPC-06-ID in Chronic Back Pain, Enters Phase 3
8.5.10 Pluristem Therapeutics: Uses PLX Cells to Secrete Therapeutic Proteins in Damaged Tissues
8.5.10.1 PLX-PAD: Phase 2 for Intermittent Claudication
8.5.10.2 PLX-PAD: Completes Phase 1/2 for Injured Gluteal Muscle
8.5.10.3 PLX-R18: In Preclinical Development for ARS
8.5.11 Regeneus: Adipose Derived MSC Therapies
8.5.11.1 Progenza Undergoing Phase 1 Trial
8.5.12 S-Evans Biosciences: Menstrual Stem Cells
8.5.13 TiGenix: Expanded Adipose-Derived Stem Cell Therapies
8.5.13.1 EASC Technology Platform
8.5.13.2 Cx601: Meets Primary Endpoint in Phase 3 Trial
8.5.13.3 The Road to Approval for Cx601 in Europe and the US
8.5.13.4 Cx611 for Rheumatoid Arthritis and also Severe Sepsis
8.5.13.5 Cx621 – Positive Results from Phase 1 Trial, but Development on Hold
8.5.13.6 ChondroCelect Already on the Market – Although is More of a Cell Therapy Rather than a Stem Cell Therapy
8.5.14 VC-01 (ViaCyte)
8.6 Genetically Modified Stem Cell Therapies
8.6.1 BluebirdBio: Gene-Modified HSCs for Orphan Diseases
8.6.2 GSK: Stem Cell Gene Therapies for Rare Diseases, Including one which has been Submitted for Approval in Europe

9. Stem Cell Non-Therapeutic Applications 2015-2026
9.1 Stem Cell Non-Therapeutic Applications: Overview and Current Status
9.2 Stem Cell Non-Therapeutic Applications: Market Forecast 2015-2026
9.3 Stem Cell Banking: Growing Demand Worldwide
9.3.1 Is there a Need for Stem Cell Banking as a Form of ‘Health Insurance’?
9.3.2 Stem Cell Banking Companies in the US and Around the World
9.3.3 Dental Stem Cell Banking: An Alternative to Cord Blood Banks?
9.4 Stem Cell Supply and Processing: iPSCs are the New Driver
9.4.1 Stem Cell Supply and Processing Companies
9.5 Stem Cell-Based Assays: Major Potential for Preclinical Screens
9.5.1 Advantages of Stem Cell-Based Assays
9.5.2 Stem Cell-Based Assay Companies
9.6 Research, Reagents, and Other Non-Therapeutic Stem Cell Activities
9.7 Drivers and Restraints

10. Qualitative Analysis of the Stem Cell Technologies and Applications Market 2015-2026
10.1 SWOT Analysis of the Stem Cell Technologies and Applications Market
10.2 Strengths
10.2.1 HSCT is Already an Established Procedure
10.2.2 Approvals for Stem Cell Therapies
10.2.3 Relaxation of Regulatory Barriers
10.3 Weaknesses
10.3.1 Uncertain Mechanisms of Action in Stem Cell Therapies
10.3.2 Phase 3 Trials only make up a Small Fraction of the Currently Ongoing Clinical Trials
10.3.3 Regulatory and Reimbursement Concerns
10.4 Opportunities
10.4.1 Huge Potential in Unmet Clinical Needs
10.4.2 Opportunities in the Non-Therapeutic Uses of Stem Cells, including Cord Blood Banking and Cell-Based Assays
10.4.3 Interactions with Related Technologies will Offer new Opportunities
10.4.4 Genetic Modification of Stem Cells
10.5 Threats
10.5.1 Financial Risks and Under-Capitalisation of the Stem Cells Sector
10.5.2 Threat of Pipeline Failures
10.5.3 Long-Term Safety Concerns
10.6 STEP Analysis of the Stem Cell Technologies and Applications Market
10.7 Social Factors
10.7.1 Increasing Burden of Disease as World Population Ages
10.7.2 Biological Insurance Through Stem Cell Banking
10.7.3 Stem Cell Tourism: Both an Opportunity and Threat to the Market
10.8 Technological Factors
10.8.1 Increasing Research Output
10.8.2 IPSC Advances
10.8.3 Greater Understanding of Stem Cell Differentiation
10.8.4 Interactions with Other Technologies
10.8.5 CRISPR: A Breakthrough in Genome Editing
10.9 Economic Factors
10.9.1 Grey Market for Stem Cell Therapies
10.9.2 Broad Changes in Pharma / Healthcare Markets
10.9.3 New Business Models are Required due to the Unique Challenges Posed by these Non-Traditional Therapies
10.10 Political Factors
10.10.1 Controversies over Embryonic Stem Cell Research
10.10.2 Support from National Governments
10.10.3 Patient Pressure to Deregulate the Stem Cell Therapies Market

11. Research Interviews
11.1 Interview with Dr. Artur Isaev, General Director of Human Stem Cells Institute (HSCI)
11.1.1 On the Skepticism Surrounding Cord Blood Banking
11.1.2 Waiting on Russian Government to Introduce Important Legislation
11.1.3 Current Strengths and Weaknesses of the Stem Cell Therapy Market
11.1.4 On Competition Within the Market
11.1.5 Future Prospects for Cord Blood Stem Cell Banking
11.1.6 How Often are Stored Cells Used?
11.1.7 Increasing Stem Cell Banking Services
11.1.8 Progress with Gemacell and Cryocell
11.1.9 Opportunities in Russia and Other Markets
11.1.10 Challenges for Stem Cell Companies Over the Next Ten Years
11.1.11 Developing the Stem Cell Therapy Market
11.2 Interview with Dr. Stefanos Theoharis, Chief Business Officer at Apceth
11.2.1 Latest Developments in the Market
11.2.2 Latest Developments at Apceth
11.2.3 Big Pharma, and General Public, Attitudes Towards Stem Cells
11.2.4 Apceth’s Aims over the Next Ten Years
11.2.5 Strengths, Opportunities and Challenges
11.2.6 Competition within the Stem Cell Market
11.2.7 Differences between Regions with Regards to Stem Cells
11.2.8 How the Stem Cell Industry Needs to Improve over the next Ten Years
11.3 Interview with MEDIPOST
11.3.1 Status of CARTISTEM Expansion Outside South Korea
11.3.2 The Latest Developments in the Market and in the Company
11.3.3 Drivers and Restraints in the Market, and Big Pharma’s Attitudes Towards Stem Cells
11.3.4 Milestones over the next Five Years
11.3.5 Strengths
11.3.6 Opportunities and Challenges
11.3.7 Product Pipeline
11.3.8 Competition in the Stem Cell Therapy Market
11.3.9 Market Differences between South Korea and the Rest of the World
11.4 Interview with Mr. Brock Reeve, Executive Director of Harvard Stem Cells Institute
11.4.1 Recent Developments in Stem Cells
11.4.2 Most Promising Techniques Over the Next Ten Years
11.4.3 Interaction Between Gene Therapy and Stem Cells
11.4.4 The Therapeutic Areas which will Benefit Most from Stem Cell Therapies
11.4.5 The Need for New Business Models for Stem Cell Therapies?
11.4.6 Steps Needed by Governments and Regulators
11.4.7 Other Trends and Developments
11.5 Interview with Dr. Leonard Zon, Director of the Stem Cell Programme at Boston’s Children’s Hospital
11.5.1 Recent Developments in Stem Cells
11.5.2 Research at Zon Laboratory
11.5.3 Most Promising Techniques Over the Next Ten Years
11.5.4 The Need for New Business Models?
11.5.5 Developing the Market
11.5.6 Other Trends and Developments

12. Conclusions
12.1 Stem Cell Technologies and Applications: An Emerging Market
12.2 Current Leading Segments and Regional Markets
12.3 World Stem cell Technologies and Applications Market Forecast 2015-2026
12.4 The Future of the Stem Cell Market
12.4.1 Concluding Remarks